Recruiting
An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread - CA030-001
Updated: 30 January, 2019 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least 1 lesion accessible for biopsy - Eastern Cooperative Oncology Group Performance Status of 0 or 1 - Participants must have received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to solid tumor histologies Exclusion Criteria: - Participants with primary CNS malignancies or tumors with CNS metastases as the only site of disease, will be excluded - Prior anti-cancer treatments such as chemotherapy, radiotherapy, or hormonal are permitted - Participants with other active malignancy requiring concurrent intervention Other protocol defined inclusion/exclusion criteria could apply
